Clinical Trial Update: Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of LC350189 [Phase 1]

View source ↗

Summary

Phase 1 study of the investigational agent LC350189 in hyperuricemia and gout assessing safety, tolerability, and pharmacokinetic/pharmacodynamic characteristic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gout
• Hyperuricemia

Drugs mentioned

• LC350189

Snippet

Sponsor: LG Life Sciences | Conditions: Hyperuricemia, Gout | Phase 1 | Status: COMPLETED